Answers are grounded in this paper and cite their sources.
The introduction of the first JAK inhibitor (JAKi) ruxolitinib 10 years ago represented a pivotal advancement in myelofibrosis (MF) treatment, mostly in terms of spleen and symptoms response. Nowadays three more JAKi, fedratinib, pacritinib, and momelotinib, are available for both ruxolitinib-resistant and naïve patients. Moreover, many drugs are currently being investigated, both alone and in combination with JAKi.
No takes yet. Share an insight, caveat, or question.
Tiribelli et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: